AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Byline: Jeremy Manier
CHICAGO _ A new diabetes treatment developed at Northwestern University has allowed some patients to stop taking insulin for more than two years, but it also has spurred ethical objections from researchers who say the trial put Brazilian children at unnecessary risk.
Thirteen of the 15 patients in the a stem-cell study went off insulin for at least six months, prompting cautious excitement from some researchers who have seen the results, to be published Wednesday in the Journal of the American Medical Association. All of the patients had the less common form of diabetes called early-onset, or Type 1 diabetes, which normally requires close blood-glucose monitoring and long-term use of insulin injections.
The new approach, designed by Dr. Richard Burt of Northwestern, enlists a patient's own adult stem cells in an effort to halt the immune system's destruction of insulin-producing "beta" cells in the…
Source: HighBeam Research, Diabetes study shows unusual promise _ and risk.